Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (20288)	4/6/1999 12:18:00 AM
From: VLAD	Respond to of 23519

SK, Last year the short interest made sure to give the Fulgham study great publicity. It took Vivus 2 days to respond. In the mean time the technical damage done to the stock price was history. I warned Vivus IR months before the conference to be ready to refute this poorly designed study but as you can see they were way behind the curve as usual. This year will be different. The lectures/reports to be presented will all be favorable for Vivus. Pay particular attention to the study done regarding the use of MUSE on Viagra failures.